Sightpath Medical Achieves Milestone of Improving the Sight of Two Million Eyes

Industry Pioneer Celebrates 20+Year History of Expertise and Innovation

BLOOMINGTON, Minn. – (September 17, 2014) – Today, Sightpath Medical, the nation’s leading provider of mobile equipment and services for cataract surgery, laser cataract surgery and refractive surgery, announces a significant milestone; the treatment of the two millionth eye by a Sightpath surgeon.

Sightpath Medical has a rich history of mobilizing sensitive ophthalmic equipment with its patented transportation systems and proven operational processes. Consistently at the forefront of ophthalmological technology and procedural advancements, Sightpath was a pioneer in the mobilization of phacoemulsifcation equipment for cataract surgery, Excimer lasers and Intralase femtosecond lasers for refractive surgery. Sightpath is the only company to offer the LenSx laser as a component of their mobile-femtosecond laser for cataract surgery platform, MoFe®. Additionally, Sightpath Medical partners with more than 1300 surgeons in 850 facilities and assists with more than 100,000 ophthalmic procedures each year on both a fixed and mobile basis.

Sightpath believes in the importance of providing surgeons and surgical facilities with customized services, preferred technologies and benefits beyond case day. More than 200 Sightpath employees serve hundreds of surgeons and facilities in both rural and urban communities across the country. Its current fleet includes more than 200 lasers and 75 fully-equipped mobile cataract vehicles, all of which are supported by manufacturer-certified laser engineers and third–party certified technicians.

“We’re excited to celebrate this milestone with the ophthalmology community and to express our sincere gratitude to every individual we have worked with throughout our 23-year history,” said Peter Flynn, President and CEO of Sightpath Medical. “Looking forward, we promise to continue our commitment as a trusted partner and resource for innovation and ingenuity.”

For more information, visit